Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)APXZF 79 Debt-to-EBITDA is 0.49 as of Jun. 2026, which is 13% below its 10-year median of 0.56. GuruFocus rates APXZF with a GF Score™ of 79/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 84.91% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Carasent AB (publ)'s Debt-to-EBITDA or its related term are showing as below:
APXZF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.07 Med: 0.56 Max: 16.95
Current: 0.36
During the past 13 years, the highest Debt-to-EBITDA Ratio of Carasent AB (publ) was 16.95. The lowest was -1.07. And the median was 0.56.
APXZF's Debt-to-EBITDA is ranked better than 84.91% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs APXZF: 0.36
Carasent AB (publ) (OTCPK:APXZF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Carasent AB (publ) Debt-to-EBITDA Related Terms
Carasent AB (publ) Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APXZF vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Carasent AB (publ) (APXZF) has a Debt-to-EBITDA of 0.49 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carasent AB (publ). This is 13% below median its historical median of 0.56. According to the industry distribution chart, Carasent AB (publ) ranks #72 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 15.1%.
Is Carasent AB (publ)'s Debt-to-EBITDA too high?
Carasent AB (publ)'s current Debt-to-EBITDA of 0.49 is 13% below median its 10-year median of 0.56. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Carasent AB (publ)'s value of 0.49 is 77.9% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #72 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #72 out of 477 companies for Debt-to-EBITDA. This places Carasent AB (publ) in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.22. Carasent AB (publ)'s value of 0.49 is 77.9% below this benchmark. While the company's 10-year median is 0.56 vs. the industry median of 2.22, Carasent AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current Debt-to-EBITDA of 0.49 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Carasent AB (publ). For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current Debt-to-EBITDA is 0.49, which is 13% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current Debt-to-EBITDA of 0.49. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current Debt-to-EBITDA is 0.49, which is 13% below median its 10-year median of 0.56 and 77.9% below the Healthcare Providers & Services industry median of 2.22. Carasent AB (publ)'s overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current Debt-to-EBITDA is 0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
Debt-to-EBITDA: 0.49 (13% below median its 10-year median of 0.56)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 77.9% below the Healthcare Providers & Services median (#72 of 477)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
79GF Score
Get the complete analysis for APXZF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
